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Abstract 
The state of the art in the investigation of drugs release from Silica-based ordered 
Mesoporous Materials (SMMs) is reviewed. First, the SMM systems used like host 
matrixes are described. Then, the model drugs studied until now, including their 
pharmacological action, structure and the mesoporous matrix employed for each drug, 
are comprehensively listed. Next, the factors influencing the release of drugs from 
SMMs and the strategies used to control the drug delivery, specially the chemical 
functionalization of the silica surface, are discussed. In addition, how all these factors 
were gathered in a kinetic equation that describes the drug release from the mesoporous 
matrixes is explained. The new application of molecular modeling and docking in the 
investigation of the drug delivery mechanisms from SMMs is also presented. Finally, 
the new approaches under investigation in this field are mentioned including the design 
of smart stimuli-responsive materials and other recent proposals for a future 
investigation. 
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INTRODUCTION 
The application of ordered mesoporous materials like matrixes in drug delivery 
systems began in 2001 with the publication of the first article describing the discovery 
that ibuprofen could be loaded and released from MCM-41, a Silica-based ordered 
Mesoporous Material (SMM) [1]. A new class of host-guest system was thus 
established where the guest (the drug) were loaded into host (the mesoporous matrix) to 
be afterwards released by dissolution of the drug in an aqueous solvent. The fluid 
solvent, competing with the inorganic groups of the mesoporous SiO2 matrix, 
transported the drug through the mesoporous channels until it is released. The drug can 
be released as much in vitro as in vivo to a biological fluid like blood plasma to exert its 
therapeutic action in the human organism. 
From 2001, the scientific interest on this application of the SMMs has been 
exponentially growing, as it is demonstrated by the high number of publications since 
then (Fig. 1). As it can be observed in the figure, from the 2001 to 2014 over 3773 
articles and review papers were published using “mesoporous silica” and “drug 
delivery” or “drug release” as search criteria.  
 
Fig. (1). Evolution in the number of publications regarding the drug administration models from 
SMMs. Data obtained from ISI Web of Knowledge®.  
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On the other hand, if we made this search in Google Scholar® more than 27200 
results are found and 257000 doing that in Google®. This gives an idea of the interest of 
this subject for the specialized researchers and also for the whole society. 
Much has been advanced in this research field from the beginnings where the 
drug was released without know neither the adsorption and release kinetics nor the 
drug-matrix interaction mechanisms and without a control at demand of the release 
process. Nowadays, we can control the release of the drug, to know the kinetics of 
release, the interactions, essentially electrostatic, that govern the chemical interaction of 
the drug and the mesoporous matrix as well as other parameters that affect the release 
rate of the drug. 
Nevertheless, still much work remains to be done with the objective that the 
mesoporous matrixes release the drug of a selective manner in the human body. That 
supposes to carry out the drug to the site where its pharmacological action is needed and 
then release it from the matrix. That way, an intelligent drug delivery system, and not 
only controlled, would be created. 
In general, drugs are administered to human body by the following routes: oral, 
topical, inhalation, rectal or parenteral [2]. Nevertheless, the first application for the 
delivery of drugs in the humans with SMMs was not the administration by those routes, 
but to be included in clinical implants. It must be taken into account that inflammation 
and infection produce important problems in Orthopedic and Dental surgeries after the 
implantation [3-5]. For that reason, anti-inflammatory and antibiotics were the first 
drugs investigated to load SMMs, so that they were released in situ [6, 7]. Nowadays, its 
field of application was extended, with the introduction of new SMMs and drugs with 
further therapeutic actions as it will be described in this paper.  
The selection of the concrete SMM which is going to act like host for a specific 
the drug guest is essential for its correct therapeutic action. Therefore, it is necessary to 
know how to combine both factors of the more appropriate way, to establish a SMM-
drug system that increased the security and effectiveness in the administration of the 
drug. With this purpose it is necessary a deep knowledge of the characteristics of the 
mesoporous matrix and the drug, as well as the factors that regulate the interaction 
mechanisms of adsorption and release of the drug within the channels of the matrix. The 
application of in silico molecular modeling techniques, together experimental 
characterization techniques including Transmission Electron Microscopy, TEM, High 
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Performance Liquid Chromatography, HPLC, Nuclear Magnetic Resonance, NMR, and 
many others will help us to the understanding all these factors. 
This review article gives an outlook of the state-of the-art of the investigation in 
drugs delivery from SMMs and the future perspectives of research in this field. First, 
the main types of SMMs investigated for this purpose are described. The second section 
includes a comprehensive table of the SMM-drug model systems investigated until now 
classified by its therapeutic action, together another list  including representative 
examples of SMM- biological and food models. This is the core of the paper. Third 
section comprises the parameters influencing the release of drugs from SMMs including 
pore diameter, surface, pore volume, electrostatic forces, tortuosity of the channels and 
others. The fourth section presents the Higuchi model, the most used to adjust the drug 
release kinetics in these models. The fifth section describes the most common strategies 
used for control the drug release, like the matrixes functionalization with polar or apolar 
chains to tailor the drug-matrix interactions and consequently the kinetics of release. 
The sixth section describes how molecular modeling can be applied as a predictive tool 
in the release of drugs from SMMs and includes a few molecular models that have been 
reported. Finally, the main conclusions and future perspectives in this emergent research 
field are summarized. 
1. SILICA BASED ORDERED MESOPOROUS MATERIALS TO 
HOST DRUGS  
In general, SMMs have a structure or superstructure of intermediate complexity 
(mesostructure) containing pores with diameter ranging from 2 to 50 nm (mesopores). 
Ordered mesoporous materials can be or disordered and are based structurally on 
repetitive pores. Typically, they are constituted by silica or alumina exhibiting 
mesopores of uniform size. Furthermore, they can be also constituted by other oxides 
for example of niobium, tantalum, titanium, cerium, zirconium or tin [8].  
The load and release processes of a drug in a SMM, take place in the interphase 
fluid medium and porous solid. Thus, the adsorption of the drug by the matrix and the 
release process fairly depend on the nature of the porous solid. 
The synthesis of the SMM is basic to determine its nature. These materials are 
based on the sol-gel chemistry principles along with those of supramolecular chemistry. 
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To obtain ordered mesoporous materials, organic tensioactive acting as templates during 
the condensation of the inorganic precursors are used. During the process, a threshold 
value is reached, denominated critical micellar concentration, where the tensioactive 
molecules form molecular aggregates denominated micelles which are also grouped in 
supramicellar structures. In the synthesis of the SMMs the oligomers of silicate 
dissolved condense around the micelles that act as templates to form a solid that 
contains the tensioactive, which is eliminated by extraction with solvents or calcination. 
This way, and once eliminated the tensioactive agent, diverse geometries, including 
hexagonal, cubical or the lamellar that typically constitute in channels or cavities 
separated and supported by amorphous silica walls. The dimensions, topology and the 
chemical nature of the inorganic skeleton of the cavities determine the physical 
chemical properties of the mesoporous material. Such properties depend on the nature 
and concentration of tensioactive and the synthesis conditions including temperature, 
pH, saline total concentration and others. 
The type of the surfactant and the pH of the medium are the key factors affecting 
to the properties of the SMM obtained. Surfactants can be classified as cationic, anionic, 
neutral or non-ionic. The type of surfactant has great importance in the synthesis of 
mesoporous materials, since the nature of the phase is largely influenced by the 
interaction between the chemical species in solution and the surfactant. Basically, three 
types of interactions can be established: I– S+, in which the inorganic species in solution 
has negative charge (I–) whereas the surfactant is positively charged (S+); I+ S–, the case 
opposed to the previous one and the type in which both chemical species have not net 
electrical charge S0 (XI)0 (being X– the contra-anion). In all the cases it is necessary to 
consider that pH determines the charge of the chemical species that are going to form 
the inorganic skeleton of the material and consequently it controls the mechanism of 
interaction with the surfactant. Thus, the silica species in solution will be negatively 
charged at pH ≥ 9, whereas at pH neutral or weakly acidic the negative charge is very 
small, prevailing the Si–OH groups. For that reason, for the synthesis of SMMs, like 
MCM-41, MCM-48 and others, cationic surfactants (S+) like alkyltrimethyl ammonium 
bromide are performed under basic conditions, where silica species are present as 
anions (I-).  
On the other hand, for the SBA-15 synthesis, a neutral surfactant, such as 
Pluronic® P123, (HO(CH2CH2O)20(CH2CH(CH3)O)70(CH2CH2O)20H) is used at acidic 
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pH. In this case the synthesis pathway takes place through a double layer hydrogen-
bonding interaction that occurs between non-ionic surfactant (S0) and the X-I+ ionic 
pairs formed in the acidic medium. This synthetic route is used for SBA-n (n= 11, 12, 
15 and 16) and FDU-n (n= 1, 5 and 12). Other strategies based in neutral surfactants 
have also yielded to HMS and MSU families, whereas the S-I+ type, failed in the 
synthesis of SMMs when used acidic conditions, although it can be used to create the 
AMS-n family by working in basic conditions [9-11]. 
The great versatility in the synthesis of these materials is a great advantage, 
since allow its obtaining as discs, powders, microcapsules or nanoparticles, which opens 
a great number of possibilities for the administration of drugs guests. 
The necessity to create these SMMs, arise in the decade of 1990s. Their 
precursors are the zeolites, a type of silicates that are mainly used as catalysts in the 
cracking of petroleum to obtain gasoline or diesel combustibles. However, zeolites are 
microporous materials with pore diameter lower than 1 nm. This limits its applications 
to the adsorption of very small molecules, and most of drugs and biological molecules 
are greater than this size. For example, amoxicillin molecule is 1.1 nm lengths, 
erythromycin of 1.4 nm and there are many others of even bigger sizes. 
The necessity to obtain zeolites with greater pore size for the adsorption of 
molecules of greater dimensions to expand its field of application is what took to a 
group of scientists of Mobil Oil Company to synthesize a new family of compounds 
denominated M41S. These synthetic materials have pores of diameter between 2-10 nm, 
i.e. they are mesoporous but, in addition, their pores exhibit an ordered and very 
homogenous pore size distribution. Other characteristics, like high pore volumes of 
around 1 cm3/g and specific surface areas between 500-1000 m2/g, become these SMMs 
in very useful for the adsorption of elevated amounts of big molecules, like many drugs 
are.  
The first ordered mesoporous silica material used as drug host system was 
MCM-41 (Mobil Composite Matter number 41) and later on MCM-48 (Mobil 
Composite Matter number 48). Other, widely used later, was SBA-15 (Santa Barbara 
Amorphous number 15). All these structures are amorphous at the atomic scale, but they 
exhibit ordered mesostructures at the molecular scale and consist of pores in the form of 
channels [9-20]. MCM-41 has a flat hexagonal structure, whereas the one of MCM-48 
is cubical bicontinuous. 
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The SBA-15 structure is hexagonal plane like MCM-41 [21]. Nevertheless, the 
pore diameter of SBA-15 of around 9 nm (up to 30 nm with special synthesis 
conditions) is greater than the one of the approximately 3 nm of MCM-41 (can be up to 
10 nm). In addition, the SBA-15 structure also contains a microchannels system of that 
connect to the mesochannels. On the other hand, the pores of MCM-48, present a 
typical range size between 1.6 and 3.8 nm.  
The pores of MCM-41 and SBA-15 are longitudinal, whose cross-sectional 
section is similar to a hexagon, whereas MCM-48 has a tridimensional pore system, 
since the longitudinal pores produce intersections in the three directions of the space. 
These three materials, MCM-41, MCM-48 and SBA-15 have been traditionally 
used like hosts for the drug adsorption and still they are being investigated [22, 23]. 
This is due to that the inorganic silica, base of these mesoporous materials, has 
biocompatibility and a low cytotoxicity, which makes safe its administration in the 
human body.  
Fig. 2 shows the structures of MCM-48 and MCM-41 (similar to SBA-15). Later 
on, other ordered mesoporous silica materials, for that and other applications were 
investigated including FDU-5 [24], FDU-12 [25] (FDU coming from Fudan 
University), FSM-16 (Folded Sheet Mesoporous Material) [26], HMM-33 (Hiroshima 
Mesoporous Material) [27], PLGA-SiO2 (Poly-Lactic-co-Glycolic Acid) [28], SBA-16 
[29] or TDU-1 (Technical Delft University) [30].  
 
Fig. (2). Porous structures of: A) MCM-48 and B) MCM-41. (Modified from [31-33]). 
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These SMMs can be functionalized and then they are named adding to the 
acronym of the material (for example, SBA-15, MCM-41) the number of carbon atoms 
of the used alkyl chain for the inorganic functionalization (basically C8 and C18), for 
example, SBA-15-C8, the inorganic (basically - NH2 and - SH) or organic groups 
(basically -COOH) used, for example, MCM-41-NH2 or SBA-15-COOH and also 
composed like C3N
+Me2C18 or derivatives of TMS (trimethylsilyl), and others. 
Furthermore the SMMs can be doped with metals like titanium (Ti-SBA-15, for 
instance) [34] or zirconium (like Zr-MCM-41) [35] and so on.  
All the properties of the SMMs native, functionalized or doped, especially by 
their textural properties (high surface area and great internal pore volume) are much 
appropriated for the drugs adsorption, even of a great size. In addition, the ordered 
distribution of its pores with linear channels, mainly in SBA-15 and MCM-41, favors 
the homogeneity in the diffusion of drug molecules, guaranteeing the reproducibility.  
2. HOST DRUG MODELS 
The drug guests are usually loaded in the SMM by impregnation from a solution 
containing the drug at constant temperature, until reaching the time at which the 
maximum adsorption of the drug in the mesoporous matrix takes place. 
In this stage, to choose the more suitable mesoporous material for the drug 
between all the available ones is very important [36], but also is the selection of the 
drug that is going to load in the matrix.  We have comprehensively compiled all the 
host-guest, SMM-drug, models as well as the main biological materials and nutritional 
complements investigated to date to be released from SMMs (Tables 1 and 2). 
 
  
 10 
Table 1.  Drug models and silica ordered mesoporous matrixes (SMMs) investigated as 
drug delivery systems, with the pharmacological action and molecular structure. 
Categorie Drug –SMM models Molecular structures Ref. 
Analgesic Acetaminophen (Paracetamol) 
Analgesics, Non-Narcotic 
Antipyretics 
Matrix: SBA-15 
 
OH
O
N
H  
[37] 
Anti-bacterials 
 
Amoxicillin  
Antibiotic semisynthetic 
Beta-lactam 
Matrixes: SBA-15, MCM-41-
APTMS, MCM-41-CPTMS 
N
S
O
OH
O
HN
O
HO
H2N
H
 
[38, 39]  
 Ampicillin 
Antibiotic semisynthetic 
Beta-lactam 
Matrix: MCM-48-HMDS 
 
N
S
O
OH
O
HN
OH2N
H
 
[40] 
 Aztreonam 
Monobactam antibiotic 
Gram-negative infections 
especially of the meninges, 
bladder and kidneys 
Matrix: MCM-41 
O
OH
O
N
N
H
ON
S
O
O
HO O
S
N
NH2  
[41] 
 Cefalotin 
Cephalosporin first generation 
Beta-lactam antibiotic 
Matrixes: MCM-41, MCM-41-
APTES, MCM-41-VTES 
O
N
S
H
OHO
O
H
N
S
O
O
 
[42] 
 Cefalexin 
Cephalosporin first generation 
Beta-lactam antibiotic 
Matrix: SBA-15 
O
N
S
H
O
OH
H
N
O
H2N
 
[43] 
 Cefotaxime 
Cephalosporin third generation 
Beta-lactam antibiotic 
Broad-spectrum 
Matrixes: MCM-41, MCM-41-
APTES, MCM-41-VTES 
N
S
O
OH
O
H
N
O
N
O
S
N
NH2
O
O
H
 
[42]  
 Cefuroxime 
Cephalosporin second generation 
Beta-lactam antibiotic 
Matrixes: SBA-15, SBA-15-
MPTES, SBA-15-APMS, FDU-12, 
FDU-12-MPTES, FDU-12-APMS, 
MCM-41, MCM-41-APTES, MCM-
41-VTES 
 
N
S
O
HO
O
H
N
O
N
O
O
O
H2N
O
H
 
[42, 44]  
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 Ciprofloxacin 
Fluoroquinolone second-
generation  
Antibiotic 
Matrix: SBA-16-HA 
N
O
HO
N
NH
O
F
 
[45] 
 Clarithromycin 
Macrolide antibiotic 
Respirator and skin infections 
treatment 
Lyme disease treatment 
Helicobacter pylori treatment 
Matrixes: SBA-15, SBA-15-TREN 
O
O O
O
O
N
OH
HO
HO
HO
OH
O
O
OH
H
H
 
[46] 
 Doxycycline 
Tetracycline antibiotic 
Antimalarial 
Matrix: SBA-15 
O
H2N
OO
OH
OH OH
OH
HO
N
H H
 
[47] 
 Erytromycin 
Macrolide antibiotic 
Protein synthesis inhibitor 
Matrixes: MCM-48, FDU-5, FDU-
5-C8, SBA-15, SBA-15-C8, SBA-15-
C18, MCM-41, LP-Ia3d 
O
O
O
O
O
O
HO
HO
HO
OH
O
O
OH
N
 
[48-50] 
 Gentamycin 
Aminoglycoside antibiotic  
Broad-spectrum 
Ototoxic and nephrotoxic 
Matrixes: SBA-15, PLGA-SiO2 
O
O
HO
O
O
OH
HO
NH2
NH2
HN
H2N
HN
 
[51, 52] 
    Levofloxacin 
DNA replication inhibitor 
Synthetic fluoroquinolone 
antibiotic 
Matrix: MCM-41 
 
 
O
N
O
OH
O
N
N
F
 
[53] 
 Linezolid 
Synthetic oxazolidinone 
antibiotic 
Gram-positive bacteria resistant 
treatment 
Matrix: SBA-15 
ON
H
O
N
O
O N
F
 
[54] 
 Rifampicin 
Antibiotic semisynthetic 
Enzyme Inhibitor 
Antitubercular agent 
Nucleic acid synthesis inhibitor 
Leprostatic agent 
Matrix: SBA-15 
N
N
N
CH3
NH
O
O
OHOH
CH3
O
O
CH3
CH3
O
CH3
O
CH3
O
CH3
HO
CH3
OH
CH3
CH3
OH
 
[54]  
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 Vancomycin 
Glycopeptide antibiotic 
Gram-positive bacteria effective 
Penicillin-resistant 
Staphylococcus aureus treatment 
Matrixes: SBA-15, SBA-15-
MPTES, SBA-15-APMS, FDU-12, 
FDU-12-MPTES, FDU-12-APMS 
OO
Cl
HO
Cl
OH
O
O
O
NH2
OH
HO
OH
O
HO
N
H
H
N
OHOH
OH
H2N
OH
N
H
OH
HN
H
NHO
N
H
OH
OH
HO
NH
OHHO OH  
[44, 54, 
55]  
 
Anti-coagulant 
 
Coumarin 
Rodenticide 
Matrix: MCM-41 
O O
OH
HO
 
[56] 
Anticonvulsant Carbamazepine 
Antimanic  
Analgesic non-narcotic 
Matrixes: SBA-15, MCM-41 
N
O NH2  
[57, 58]  
 Diazepam 
Anti-anxiety 
Hypnotic and sedative 
Anesthetics intravenous 
GABA Modulators 
Muscle Relaxant 
Matrix: SBA-15 
 
N
N
O
Cl
 
[59] 
Anti-
depressives 
 
Sertraline 
Serotonin uptake inhibitors 
Major depressive disorder 
treatment 
Matrix: MCM-41 
Cl
ClHN
CH3
 
[60] 
  L-Tryptophan  
Dietary supplement 
Micronutrient 
Matrixes: SBA-15-C3N+Me, SBA-
15-C3N+Me2C18 
NH2
H
N
O
OH
 
[61] 
Anti-fungal Griseofulvin 
Anti-bacterial 
Skin and nails fungal infections 
treatment 
Matrix: SBA-15 
O
O
O
O
O
O
Cl
 
[59]  
 
 
Itraconazole 
Antiprotozoal 
14-alpha demethylase inhibitor 
Anticancer agent explored 
Matrix: SBA-15 
Cl
Cl
O
O
O
O
N
N
N
N
N
N
N
N
CH3
CH3
 
[62] 
 Ketoconazole 
Primarily fungal infections 
treatment 
14-alpha demethylase Inhibitor 
Matrix: SBA-15 
O
N
N
O
O
O
N
N
Cl
Cl
 
[59]  
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 Salicylic acid 
Anti-Infective 
Keratolytic 
Matrixes: SBA-15, SBA-15-NH2, 
SBA-15-COOH 
OH
O
OH
 
[63] 
 
 
 
 
 
Anti-histaminic Cinnarizine 
Piperazine derivative 
Calcium channel blocker 
Matrix: SBA-15 
N
N  
[59] 
Anti-HIV Stavudine 
Antimetabolite 
Nucleoside analog reverse-
transcriptase inhibitor 
Matrix: SBA-15 
H
N
N
O O
O
HO  
[37]  
Anti-
hyperglycemic 
Glyburide (glibenclamide) 
Hypoglycemic 
Anti-arrhythmia 
Antidiabetic 
Matrix: SBA-15 
O
N
H
O
S
O
O H
N
H
N
O
Cl
 
 
[64] 
Anti-
hypertensives 
Aliskiren 
Renin inhibitor 
Essential (primary) hypertension 
treatment 
Matrixes: SBA-15, SBA-15-MgO 
 
O
N
H
OO
O
OH
O
NH2
NH2
 
 
[65] 
 
 
Atenolol 
Adrenergic beta-1 receptor-
antagonist 
Sympatholytic 
Matrixes: MCM-41, SBA-15 
O
NH2
O
H
N
OH
 
[66, 67]  
 Captopril 
Angiotensin-converting enzyme 
inhibitor 
Matrixes: MCM-41, MCM-41-
TMCS, SBA-15, SBA-15-MgO, 
MCM-48-YVO4:Eu3+ HS
O
OH
O
N
CH3
 
[65, 68-
70]  
 
 Carvedilol 
Vasodilator  
Adrenergic alpha-1 receptor 
antagonist 
Adrenergic beta-antagonists 
Matrixes: SBA-15, MCM-41 
N
H
O
O
OH
O
NH
 
[71, 72]  
 Lacidipine 
Calcium channel blocker 
Relaxing and opening up the 
blood vessels 
Matrix: SBA-15 N
H
O
O
O
O
O
O
 
[73] 
 Metropolol 
Adrenergic receptor antagonist 
Sympatholytic 
Anti-arrhythmia  
Matrix: SBA-15-MPTMS 
N
H
O
O
OH  
[74] 
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 Nifedipine 
Dihydropyridine 
Calcium channel blocker 
Chronic stable angina 
Matrix: SBA-15 N
H
O
O
O
O
N+
O
-O
 
[59, 75]  
 Nimodipine 
Dihydropyridine 
Calcium channel blocker 
Vasodilator 
Matrix: SBA-15 
HN
O
O
OO
N+
O O-
O
 
[76] 
 Propanolol 
Anti-arrhythmia 
Vasodilator 
Adrenergic beta-antagonist 
Matrix: MCM-41 
O
OH
N
H
CH3
CH3
 
[77] 
 Ramipril 
Angiotensin-converting enzyme 
inhibitor 
Congestive heart failure 
treatment 
Muscle relaxant 
Matrix: SBA-15 
N
O
OH
O
N
H
O
O
H
H
 
[78] 
Anti-
hypocalcemics 
 
Alendronate 
Bone density conservation agent 
Antiresorptive 
Matrixes: SBA-15, SBA-15-NH2, 
SBA-15-PO4, MCM-41, MCM-41-
NH2 
P
P
OH
OH
OH
HO
HO
O
O
NH2
 
[79-85]  
 Zolendronate 
Bone density conservation agent 
Antiresorptive 
Matrix: SBA-15 
 
P
O
HO
HO
N
N
OH
P
OH
HO
O
 
[86, 87]  
Anti-Infectives 
 
Chlorhexidine 
Disinfectant 
Mouthwashes 
Matrix: MCM-41 
NH
H
N
N
H
NH
H
N
N
H
NH
H
N
N
H
NH
Cl
Cl
 
[88] 
 Nitrofurazone (nitrofural) 
Bactericidal 
Antibiotic 
Matrix: MCM-41 
N
H
O
NH2
N
O
N+
O
-O
 
[89] 
 
 Sulfadiazine 
Coccidiostat antiprotozoal 
Matrixes: SBA-15, MCM-41, 
MCM-41-NH2, MCM-41-COOH, 
SBA-15-COOH 
S
O
O
H
N
H2N
N
N
 
[90] 
 15 
Anti-
inflammatory 
non-steroidal 
 
Aspirin (Acetylsalicylic acid) 
Fibrinolytic  
Antipyretic 
Cyclooxygenase Inhibitor 
Matrixes: MCM-41, MCM-41-Al, 
MCM-41-APTES, SBA-15 
O
OHO
O
H3C
 
[91-94]  
 Diflunisal  
Salicylic acid derivative 
Analgesic 
Matrix: MCM-41-Al O
OH
OH
F F  
[95] 
 Fluribuprofen 
Analgesic non-narcotic 
Cyclooxygenase Inhibitor 
Matrix: FSM-16 
F
HO
O
H3C
 
[26]  
 Ibuprofen  
Analgesic non-narcotic 
Cyclooxygenase Inhibitor 
Matrixes: MCM-41, MCM-41-
NH2, MCM-48, LP-Ia3d, FDU-5, 
SBA-15, TDU-1, MCM-41-HMDS, 
MCM-41-AEPTMS, MCM-41-
APTES, MCM-41-DMS, MCM-41-
TMS, Ti-SBA-15, SBA-15-GA 
 
OH
O
CH3
CH3
CH3
 
[1, 30, 
49, 96-
106]  
 Indomethacin 
Cyclooxygenase Inhibitor 
Cardiovascular 
Tocolytic 
Gout Suppressant 
Matrixes: MCM-41, SBA-15, SBA-
16 
Cl
O
O
OH
O
N
CH3
H3C
 
[59, 64, 
107, 
108]  
 Ketoprofen 
Analgesic 
Antipyretic 
Cyclooxygenase inhibitor 
Matrix: SBA-15-APTES 
HO
O
O
CH3
 
[109] 
 Mesalazine 
Inflammatory bowel disease 
treatment 
Ulcerative colitis treatment 
Matrixes: MCM-41, MCM-41-
NH2, MCM-41-COOH 
HO
OHO
NH2  
[110] 
 Naproxen  
Analgesic 
Antipyretic 
Matrix: MCM-41 
O
OH
CH3
O
CH3  
[111] 
 Phenylbutazone 
Analgesic 
Antipyretic 
Matrix: SBA-15 
O
O
N
N
CH3
 
[59]  
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 Piroxicam 
Oxicam class 
Arthritis treatment 
Cyclooxygenase inhibitor 
Matrixes: MCM-41, SBA-15 S
N
HN
N
CH3
OH
O
O O  
[112, 
113] 
Anti-
inflammatory 
steroidal 
 
Dexamethasone 
Glucocorticoid 
Antineoplastic 
Antiemetic 
Matrixes: SBA-15, MCM-41  
 
F
HO
HO O
OH
O
CH3
CH3H3C
HH
 
[114] 
 Methylprednisolone 
Glucocorticoid 
Antineoplastic 
Matrixes: SBA-15, SBA-16, MCM-
41, FDU-12 
HO
HO
O
OH
O
CH3
CH3
CH3
HH
H
 
[115] 
 Prednisolone 
Glucocorticoid 
Antineoplastic 
Matrixes: SBA-15, SBA-3, FDU-12 
 
HO
HO
O
OH
O
CH3
CH3
HH
H
 
[116] 
Anti-lipemic Fenofibrate 
Fibrate class 
Hypolipidemic 
Reduces LDL and VLD levels 
increasing HDL levels 
Reduces triglycerides level 
Matrix: SBA-15 
 
ClO
O
O
O
CH3
CH3
CH3
CH3
 
[59]  
Anti-
neoplastics 
 
Camptothecin 
Phytogenic 
Topoisomerase I Inhibitor 
Matrix: MCM-41 
 
O
O
O
HO
CH3
N
N
 
[117, 
118]  
 Cisplatin 
Cross-linking reagent 
Radiation-sensitizing agent 
Matrixes: MCM-41, SBA-15, 
MCM-41-APTES, MCM-41-PNTES 
Cl
Cl
Pt
H2N
H2N
 
[119, 
120] 
 Desatinib 
Tyrosine kinase inhibitor 
Chronic myelogenous 
leukemia agent 
Matrix: SBA-15 
S
N
O
H
N NH
N
N
N N
OH
Cl
 
[121] 
 
 Doxorubicin 
Anthracycline antibiotic 
Administered only into a vein 
Isolated from cultures of 
Streptomyces peucetius var. 
caesius 
Matrix: SBA-15-FA 
OO
HO
HO
OH
OH
O
HO
O
O
O
NH2
H3C
CH3
 
[122] 
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 Irinotecan  
Phytogenic 
Radiation-sensitizing agent 
Topoisomerase I inhibitor 
Prodrug 
Matrix: MCM-41-NH2 
O
O
O
HO
O
O
N
N
N
N
CH3
CH3
 
[123] 
 
 Methotrexate 
Antirheumatic 
Folic acid antagonist 
Nucleic acid synthesis inhibitor 
Matrix: MSM-Al 
 
O OH
O
OH
O
N
H
N
N
N
N
N
NH2
H2N  
[124] 
Anti-
thrombotic 
Cilostazol 
Fibrinolytic  
Platelet Aggregation Inhibitor 
Bronchodilator  
Phosphodiesterase 3 Inhibitor 
Vasodilator 
Neuroprotective 
Matrixes: MCM-41, MCM-48 
O
O
N
N
N N
N
H  
 
[125] 
Anti-ulcer 
 
Famotidine 
Histamine H2 antagonist 
Matrixes: SBA-15, SBA-15-
COOH, SBA-15-COOH-TMS, 
MCM-41, MSU-1 -2 -3 
 
S
S S
O
O
N
NH2N
N
H2N
NH2
H2N
 
[126-
128] 
Diuretic Furosemide 
Sodium potassium chloride 
symporter inhibitor 
Matrix: SBA-15 
Cl
SO
O
O
OH
O
HN NH2
 
[129] 
Endiometriosis 
treatment 
Danazol 
Synthetic steroid ethisterone 
Gonadotrophins suppressor 
Matrix: SBA-15 
HO
O
N
CH3
CH3
CH
HH
H
 
[59]  
Steroid Progesterone 
Progestins 
Contraceptive Agents 
Matrix: SBA-15 
O
O
CH3
CH3
CH3
HH
H
 
[37]  
List of abbreviatons: APTMS: 3-aminopropyltrimethoxysilane; CPTMS: 3-chloropropyltrimethoxysilane; 
HMDS: hexamethyldisilazine; APTES: 3-aminopropyltrietoxysilane; VTES: trietoxyvinylsilane; APMS: N-(2-
aminoethyl)-aminopropyl dimethoxymethylsilane; MPTES: 3-mercaptopropyl triethoxysilane;  HA: Calcium 
phosphate hydroxyapatite; TREN: tris(2-aminoethyl) amine; TMCS: trimethylchlorosilane; MPTMS: 3-
mercaptopropyl trimethoxysilane; HDMS: 1,1,1,3,3,3-hexamethyldisilazane; AEPTMS: 3-(2-aminoethylamino) 
propyltrimethoxysilane;  DMS: dimethyl sulfide; TMS: tert-butyl mercaptan; GA: glutaraldehyde; PNTES: 3-
propanonitrile triethoxysilane; FA: Folic acid; MSU: Michigan State University mesoporous matrix. 
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Table 2.  Biological and food models in SMMs used as delivery systems. 
Biological &Food-matrix models Molecular structures References 
Allyl isothiocyanate  
Flavouring agent 
Rubefacient 
Cancer chemopreventive in vitro 
Matrix: SBA-15 
 
N
C
S
 
[65, 130] 
Bovine serum albumin (BSA)  
Transport protein 
Biochemical applications 
including immunohistochemistry 
and immunoblots 
Matrixes: SBA-15, SBA-15-NH2  
[131, 132] 
 
Chicago Sky Blue 6B 
Potent L-glutamate inhibitor 
Matrix: SBA-15 
 
 
 
 
Na+
Na+
Na+
Na+
SO O
O-
S
O
O
-O
O
N
N
H
O
O
H
N
N S
O
O
O-
S OO
O-
O NH2
NH2
 
[133] 
Pentagastrin 
Pentapeptide synthetic 
Effects like gastrin 
Diagnostic agent 
Matrix: MSU-Tween-80 
 
 
S
O
O
OO
OH
O
O
O
O
H
NHN
N
H
HN
HN
HN
H2N
CH3
CH3
CH3
 
[134] 
 
L-Phenylalanine 
Intermediate neuriotransmisor 
Dietary Supplement 
Micronutrient 
Matrixes: SBA-15, SBA-16 
NH2
O
OH
 
[135] 
PTHrp (107-111) osteostatin 
Bone formation regulator 
Matrix: SBA-15 N O
H
H
H
H
H
N
O
H
H
H
H
H
H
HH
N
O
O
O
H
H H
H
H
H
NO
H
H
HHH
N
O
H H
H
H
H
H
H
H
H
H
H
H H
H
 
[136] 
Zn(II) benzoate complexes 
Food preservative 
Bactericidal  
Insecticide amd acaricid 
Matrix: SBA-16 
OO
benzoate ligand 
[137] 
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Fig. (3). Summarizing of Tables 1 and 2 to visualize more clearly the main SMMs and families and 
drugs investigated until now as host-guest systems. 
 As it can be observed in Fig. 3, SBA-15 and MCM-41 matrixes are, as much, the 
more profusely matrixes investigated until now because both together represent 76% of 
the mesoporous systems studied. Regarding the families of drugs released, the situation 
is more balanced although three categories: antibacterials, antiinflammatory and 
hypertensives represent the 50% of total. However, the category of antineoplastics is 
trending to increase, reaching a great importance in the actual research in mesoporous 
nanoparticles, which are out of the scope of this article.   
Therefore, the selection of the SMMs for a specific drug is not simple if we treat 
to find a host-guest pair for the optimal release of the drug. In principle, such selection 
must be randomized in a trial and error strategy with the different SMMs and drugs 
available. Nevertheless, this task cost time and money and, sometimes, it is not reliable. 
Initially, the SMM was chosen considering only the size of the drug molecule. With this 
single parameter, almost any SMM would be valid to host the most part of the drugs 
investigated. However, although the drug was small enough to penetrate into the pores 
of the matrix, other factors must be considered. For instance, the lipophilic or 
hydrophilic nature of the drug can be incompatible with the matrix. Moreover, the SMM 
and drug can present electrostatic charges repulsion. Anyone of these factors would 
prevent the use of that matrix for that specific drug. 
One of the technological ways to solve this problem of absorption via oral in 
these drugs is the guest-host system drug-SMM that helps to the drug absorption 
because it is encapsulated in the matrix. That is an important application of the 
mesoporous silica matrixes. The resolution of this technical problem can be reached 
with other materials, but the added value of the SMMs is, in general, that they are able 
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to adsorb great amounts of water. This ability of SMMs is important for an effective 
entrance and delivery of the drug. It is necessary to consider that the drug when released 
it is linked to the matrix in dry conditions and it must be dissolved by the aqueous fluid 
coming into the SMM channels. Thus, it is established a concentration gradient favored 
by the fast absorption of the fluid into the pores of the mesoporous material. 
However, there are more aspects that must be taken into consideration. For 
instance, a drug can be essentially lipophilic, like ibuprofen, or essentially hydrophilic, 
like vancomycin [138]. This fact not only influences its absorption in the organism, but 
it is also an important parameter to consider in the delivery of a drug from a hydrophilic 
silica matrix that does not dissolve in aqueous fluids. 
Therefore, in the election of a drug model for its delivery from SMM, besides 
the size of the molecule, it is necessary to consider other factors related with the 
diffusion or the interactions with the matrix, as it will be detailed in the next section. 
On the other hand, to know if a drug was loaded in a SMM, indirect methods 
were used, for instance determining the reduction of the surface area and pore volume 
of the matrix. This changed when for the first time Vallet-Regi et al [139] in 2010 used 
the Scanning Transmission Electron Microscopy (STEM) to visualize with atomic 
resolution the SBA-15 and SBA-15-NH2 SMMs. STEM equipped with aberration 
corrector is able to determine the distribution of silicon, oxygen, nitrogen and carbon, 
through the mesoporous silica network. This way, the presence of zolendronate inside 
the channels of the mesoporous matrix was confirmed. 
Nevertheless, to obtain the total amount of drug adsorbed in a SMM it is 
necessary to use indirect methods like thermogravimetry, porosimetry and other 
methods of chemical analysis [140-146]. 
3. FACTORS INFLUENCING THE DRUG RELEASE FROM 
SILICA ORDERED MESOPOROUS MATRIXES  
In this section, the main factors that take part in the process of release of a drug 
from SMM, in their great majority common and related to the process of adsorption of 
the drug in the matrix, are described. 
3A. Pore diameter 
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As we previously established, the diameter pore that acts like selective sieve, 
determines if a drug, by size, can penetrate into the pore channels [131]. This way, and 
considering only the sieve effect of pores, although any SMM would be suitable to 
adsorb small size drugs, MCM-41 usually is used due to its great stability. In addition, 
MCM-41, as MCM-48 and SBA-15, presents the advantage to be easily functionalized, 
which has great importance in the controlled release of drugs guests, as we will see 
later.  
As an example and due to its small size, ibuprofen can be loaded in any SMM. 
For other drugs of greater size like the glycopeptide vancomycin (C66H75Cl2N9O24) or 
others of similar size, it is preferable to use SBA-15 as first option to be sure that these 
drugs will be able to be included within its pores [54, 147-150].  
In any case, it is necessary to notice that the fact that a drug can penetrate by size 
within pores does not guarantee that this will happen, because there are other factors 
that influence, as we will see ahead in an example of application of molecular models. 
Such factors can produce a rejection of the drug molecules by the inorganic or organic 
components of the channels of the mesoporous matrix.  
3B. Surface 
 When the drug to be loaded is of a size much smaller than the pores of the 
matrix, most of the drug molecules are not adsorbed to the pores surface. This is due 
that only a few of them can directly interact with the matrix surface and the remaining 
molecules do not interact with the surface and they are not retained. This is a relevant 
fact that was investigated by Vallet-Regi et al. in a model of alendronate from MCM-41 
and SBA-15 matrixes [131]. Experimental results of Vallet-Regí et al indicate that 
MCM-41 is able to load more alendronate than SBA-15 (surface area= 719 m2/g) 
because in MCM-41 (surface area= 1157 m2/g) the contact surface with alendronate is 
higher than that of SBA-15. 
The molecules are confined inside the pores through the attractive interaction 
with the internal mesopore walls. It is rational to consider the opposite process, that is 
the release of the adsorbed drug, will also depend on the material surface area. In fact, 
different experiments have shown that when the surface area of a SMM is very high, 
there is a great molecular retention and as a result a slower drug release in comparison 
with materials exhibiting smaller surface areas. The extra interactions of the drug 
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molecules with a higher surface available are responsible of retard in the kinetics of 
release of the drug [131]. 
3C. Pore volume 
 Pore volume is an important parameter for great size molecules. The pore 
volume determines the available space to load molecules of drug. Whichever greater is 
the pore volume, greater will be the load [151], which also influence the drug release. In 
case of small volume of pores, the channel of the matrix could be occluded with the 
drug molecules.  
3D. Electrostatic forces 
When the drug contacts with the mesoporous matrix, interactions by electrostatic 
forces of the partial charges produced by the movement of the electrons are established. 
The native silica in normal conditions has negative electrostatic charges with uniform 
zones of a great electron density. However, the drug molecule can be exclusively 
charged by positive charges, with deficit of electrons, negative, rich in electrons, or, the 
most habitual case, to exhibit zones of partial charges positive and negative in different 
positions of the molecule. It is understood that if the charges are of equal sign, they will 
be repulsed. Therefore if the drug is highly charged of negative electronic density, 
cannot penetrate into the pores, although it could be possible if size were the only 
criterion.  
Nevertheless, when electrostatic forces of different sign between the guest and 
the mesoporous host are established, they must influence the drug retention in the 
matrix channels. We will come back to it when we will study the application of the 
molecular modeling to the drug release from SMMs. 
3E. Tortuosity of the channel  
In the diffusion of the drug through a porous matrix, a factor to consider is the 
tortuosity of the channel. Nevertheless, and due to the property of SMMs to adsorb 
great amount of fluid as a sponge and the homogeneity and linearity of its channels, 
tortuosity is not a significant factor in the release of the drug from a SMM even in a 
priori more winding materials like MCM-48.  
The fact that the material tortuosity does not significantly affect the kinetic of 
release was shown in a model with ibuprofen and MCM-48 and SBA-15 like matrixes. 
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Izquierdo-Barba et al [152] experimentally demonstrated that there are no significant 
differences in the velocity of delivery of ibuprofen from MCM-48 and SBA-15, 
according to the obtained values using the Noyes-Whitney equation and the application 
of the first Fick´s law [153].  
3F. Other factors 
Another factor to be considered is the lipophilic or hydrophilic nature of the 
guest-host system. In principle, the mesoporous silica matrix is hydrophilic and does not 
dissolve in water, but that can change if the material is modified after be functionalized. 
This parameter influences both the adsorption of the drug and its delivery. 
Other factors that influence the delivery of a drug, like pH, temperature or 
pressure, usually are kept constants in the trials. Being thus, they cannot influence in the 
kinetic of release of the drug. But if they are modified those three parameters exert their 
influence in the release process. For instance, Rosenholm et al [154] demonstrated that 
the interface chemistry of SBA-15 is pH dependent and it is controlled by the type of 
silanol groups (Q2 (Si(OH)2(OSi)), Q
3 (Si(OH)(OSi)3) and Q
4 ((Si(OSi)4)).  
 Finally, is necessary to consider that the singular SBA-15 micropores that 
connect the mesoporous channels are too small so that the drugs commonly used as 
models are introduced into them. For this reason they do not influence the delivery of 
the drug and they are not considered as a factor that takes part in the drug release. 
The challenge consists in the evaluation of the specific participation of each 
factor that govern the drug delivery, to be able to find out how it works their mechanism 
of action and to act consequently, to release the drug in a controlled way. 
4. RELEASE KINETICS OF THE DRUG 
Once established the main factors that take part in the release of a drug from 
SMMs it is necessary to establish the type of kinetic that is going to govern that process. 
In the materials that we are reviewing, the objective is that the drug was released in vivo 
from the matrix by a biological fluid. Due to it, in the kinetic tests of drug delivery a 
common alternative is the use of solutions mimicking plasma, like the Simulated Body 
Fluid (SBF) proposed by Kokubo et al [155], isotonic serum or just a buffer at pH 7. In 
addition, to simulate better the in vivo conditions of plasma temperature usually is about 
37ºC at atmospheric pressure and all under stirring. 
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Like in the process of adsorption of the drug in the mesoporous matrix, the drug 
can be adsorbed in the outer or in the inner part of the channels. Thus, two delivery 
stages are observed. The molecules of drug adsorbed in the outer part of the matrix are 
quickly released, whereas the adsorbed ones within the channel exhibit a slower kinetic, 
since the diffusion of the drug is faster on the surface that within the pores. 
The fact that it is not possible in principle, to establish a traditional kinetics of 
order, zero, one or two, in the kinetics of administration, delivery and degradation of a 
drug, it is difficult to compare different kinetic models mesoporous matrix-drug. To 
solve this problem made the mesoporous models comparable to each other, Higuchi 
[156] established being based initially on the Fick´s law, one kinetic equation: a = kt ½ 
to calculate the constant observed of the reaction of release (k), that makes it dependent 
on the square root of the time (t ½) and the concentration of the drug (a). This equation, 
adapted for the first mesoporous material-drug model, is suitable for a model of release 
of the drug from the matrix when the diffusion takes place through pores full of 
dissolvent. Then, it establishes that the equation is: k= f (D, ε, τ, C, A), reuniting the 
main factors that take part in the release of a drug since D is the diffusion of the drug in 
the dissolvent, τ the tortuosity factor of the system, ε the porosity of the matrix, A the 
total amount of drug in the matrix and C the solubility of the drug in the solvent used.   
Thus, the release of the drug can be experimentally evaluated by the calculation 
of the kinetic constant observed for the drug release from the matrix for concentrations 
or percentages of release of the drug determined by using analytical techniques such as 
UV spectrometry or HPLC. In addition, the percentage (or milligrams) of drug released 
with time can be represented by a straight line. A typical profile of kinetic of release in 
a SMM - drug model in which a first stage of quick release is observed and later a 
sustained release (Fig. 4). 
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Fig. (4). Release of a drug from a SMM. A) Quick stage. B) Sustained step. (Unpublished results) 
 Higuchi equation that is applied in these models was modified by several 
authors, for example Dash et al [157], introducing new factors, to make it more 
effective.  
5. CONTROLLED RELEASE OF DRUG: FUNCTIONALIZATION  
In the initial works of drug release from SMMs of MCM-41 and SBA-15, it was 
still not had knowledge sufficient to obtain a really controlled delivery of the drug. For 
example, in the pioneering work of Doadrio et al [52] they demonstrated that it is 
possible to load and release a drug of greater size than ibuprofen used like first model 
from a SMM with pore diameter greater than that MCM-41, also used till then like a 
model, without collapse the matrix channels. It was an important first step. But the 
model of gentamicin-SBA-15 used, like other contemporary ones, although very 
reproducible does not control at demand the delivery of the drug. 
In that work, it is demonstrated that the kinetic of release is time dependent and 
that it is similar as much in the material as powders or as pellets. In the plot of 
gentamicin release (Fig. 4) the two stages described in the previous section are 
observed. In the first one, a fast delivery (60%) of the drug takes place in the first hour, 
attributed to its weak interaction in the surface of the matrix. In the second, a slower 
delivery of gentamicin (up to 100%) takes place until 24 h, due to the progressive 
release of the drug from the interior of the pores of the matrix [49]. This will be 
confirmed later with the application of molecular modeling and docking techniques. 
Results of similar profiles of release following the kinetics of Higuchi with other 
drugs, like the amoxicillin, were obtained [38]. Nevertheless, in this case, the drug 
release from the SBA-15 is more sustained. Indeed, there are not two identical models, 
reason why in the interpretation mechanism of release of a drug, we only have the 
security that is valid for the considered drug-matrix model, but in another model it could 
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be different. However in this review paper of computer-assisted mechanical-quantum 
models has not been considered yet. 
A considerable advance in the effective control of the drug release from SMMs, 
took place when the silica base of the matrix was functionalized. This functionalization 
allows an effective control on the kinetics of release of the drug, through several factors. 
In the first place, since the size and tortuosity of pores are inherent to the internal 
structure of the matrix, if they are modified, is carried out an alteration of the flow and 
therefore, also of the kinetic of delivery of the drug, that can be slowed down. The 
functionalization involves a decrease in the diameter and volume of pores, by the 
interaction of new groups to the silica matrix, which increases the tortuosity of the 
channel. Second, the hydrophilic capacity of the silica is modified, which can diminish 
until be converted into a lipophilic matrix, if we introduce sufficient number of carbon 
atoms, or conversely it can be increased if including new highly hydrophilic groups. 
Finally, new electrostatic drug-matrix interactions will be established, which will 
diminish or increase the negative electron density of silica surface.  
In addition, drug-matrix hydrogen bonds can be established and even between 
two groups of matrix when is functionalized with - NH2 groups, that also must be 
considered. Functionalization of the matrix with apolar groups can be obtained (i.e. 
C18, C8) or with polar groups (like -NH2, -SH, -COOH). For example, the 
functionalization with C8 and C18 chains are made introducing 
octyldimethylchlorosilane molecules (CH3(CH2)7Si(CH3)2Cl) or octadecyldimethyl 
chlorosilane (CH3(CH2)17Si(CH3)2Cl), respectively, over the silica surface, which will 
react to interact the carbon chains and the silanol groups. In this way the lipidic 
character of the material is increased.   
The question is what percentage of silanol groups is functionalized. In the case 
of the functionalization with C18 chains, very voluminous alkyl silane chains are 
created that are randomly arranged, reason why all cannot react with the silanol groups 
by steric effect. That way, approximately the 2.5% of -OH groups in the silica surface 
remains unreacted [158]. Thus, if the functionalization is made in the suitable 
conditions, the channels of the mesoporous material would not be occluded. 
Nevertheless, the functionalization can lead in some cases, an obstruction of the 
mesoporous material pores. For example, Izquierdo-Barba et al. [49] discovered that the 
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functionalization of MCM-48 with C18 chains covers all the pores of the mesoporous 
material and prevents the access of the drug to the inner of the channel.  
The release is generally slower from the functionalized matrix, with respect to 
not functionalized. A comparative example of the modification of the vancomycin 
kinetic release when SBA-15 is functionalized with C8 is shown in Fig. 5. In the figure, 
a smaller velocity of release in the functionalized material (k= 0.068 min-1/2) with 
respect to not functionalized is observed (k= 0.89 min-1/2) [55]. In analogous studies 
differences between the functionalized and non-functionalized matrixes regarding the 
drug delivery were also observed [159]. 
 
Fig. (5). Profiles of the delivery plots of a model of vancomycin in: A) SBA-15 and B) SBA-15-C8 
(Modified form [55]).  
In a study about the influence of the matrix functionalization in the drug 
delivery, functionalizing SBA-15 with C8 and C18 chains and using erythromycin as 
model drug, it was demonstrated that the release rate diminishes when the number of 
hydrophobic –CH2- groups – increased [48].  
Therefore, it has been demonstrated that, with the suitable functionalization, the 
release of a drug from a SMM can be controlled.  Nevertheless, with the data described 
until now all the factors that govern the adsorption and delivery of the drug in the 
mesoporous matrix are not completely described. This situation changes when 
molecular modeling analysis is combined together with the  experimental data that we 
will describe in the following section. 
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6. MOLECULAR MODELING APPLICATION TO SILICA 
ORDERED MESOPOROUS MATERIALS – DRUG SYSTEMS 
The recent introduction of the in silico molecular modeling analysis in the the 
drug release investigation from SMMs, supposes a significant advance in the 
interpretation of the drug-delivery mechanism from mesoporous matrixes, since it 
allows establishing the interactions by electrostatic charges and hydrogen bonds in the 
guest-host models. 
The importance of using these models in chemistry was recognized in 2013 with 
the concession of the Nobel Prize in Chemistry to Karplu, Levitt and Warshel by the 
development of multiscale models of complex chemical systems [160]. These advanced 
models are tools mainly predictive, that allows approaching reality and can to establish 
if a reaction is going to happen or no, to design new materials or drugs, to know how 
certain proteins respond to polluting agents or drugs, to determine the interactions drug-
receptor and more applications. At the moment, these models have such predictive 
power that Chemistry experiments can be done in computer instead of in the 
conventional laboratory, which saves time and money. 
  Appling this techniques to the silica-based ordered mesoporous materials and 
with appropriate software, it can be constructed the structure of a mesoporous material, 
such as MCM-41 and SB-15 in a 3D representation. Then, the minimum energy 
configuration, the electrostatic potential map, and other parameters of this structure can 
be calculated by semiempirical or ab initio mechanical-quantum methods. These 
calculations facilitate the comprehension of the mechanism of release of the drugs 
because the power of the computer calculations of the theoretical models provides the 
necessary information to understand these processes. For that reason, they must become 
in essential tools for experimentalist chemical, in general, and specifically for the study 
of the SMMs. 
For instance, it could be constructed the electrostatic potentials maps of the 
drugs included in Table 1, that could be used, among other applications, to predict what 
functional group of the drug molecule interacts with the matrix of silica, native or 
functionalized. This can be visualized by a representation in a gradient of molecular 
electrostatic potentials map that has been obtained from the mechanical-quantum 
calculations. In these map the atom zones rich in electrons are usually represented in red 
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and the deficit in electrons in blue. Other colors (green and yellow) usually are uniform 
and representative of covalent bonds or electron delocalization of pi bonds.  
Next a representative example of the application of these electrostatic potential 
maps the SMM-drug system based ibuprofen is presented. If we observed at detail this 
electrostatic potential map optimized by an ab initio method (Fig. 6), zones of negative 
charges rich in electrons and others of positive charge can be observed. Nevertheless, 
zones of positive charge predominate in the molecule. The figure also shows that the 
positive charges are mainly oriented towards the outer part of the molecule. This way, 
and because ibuprofen molecule is small enough to penetrate into the porous channels 
of the matrix it will be more probable that this molecule interact with the negatively 
charged silica matrix (dark grey contrast in Fig. 7). 
Another example is the vancomycin molecule, whose electrostatic potential map 
(Fig. 8) displays also two parts of different sign like ibuprofen. In this case predominate 
the zones with great electron density (negatively charged) but vancomycin molecule 
also exhibit a well differentiated part positively charged that is susceptible to establish 
electrostatic interactions with the negatively charged silica matrix. 
 
 
Fig. (6). Map of electrostatic potential of ibuprofen. (Unpublished results). 
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Fig. (7). Adsorption of a molecule of ibuprofen within the MCM-41 channels by electrostatic 
interactions. (Unpublished results). 
 
 
Fig. (8). Map of electrostatic potential of vancomycin. (Unpublished results). 
 
These theoretical models must be compared with the experimental data as it was 
reported by Doadrio et al in a vancomycin/SBA-15 model [55]. In that work, a MCM-
41 channel, similar to SBA-15 but with somewhat smaller pore diameter, was modeled 
to simulate the electrostatic interactions that take place with the vancomycin. That way, 
it was demonstrated that in that case the electrostatic attractions between the matrix and 
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the drug influences decisively the kinetic of delivery of the drug. Fig. 9 shows the 
channel simulations of MCM-41 (Figs. 9A and 9B) and the optimized structure of 
vancomycin (Fig. 9C). This last one shows that the molecule optimized of vancomycin 
is folded and by dimensions (1.77 nm) could penetrate into the pores of the MCM-41 
model (Fig. 9A) of 2.01 nm of diameter (MCM-412.01) and consequently in the bigger 
ones of SBA-15. Moreover, the vancomycin molecule can be located in the outer part of 
the channel as is shown in Fig. 9B. 
 
Fig. (9). Molecular modeling of: A) Complete MCM-41 optimized channel. B) Shorter MCM-41 
channel to short the simulations time when vancomycin molecule is included. C) Molecule of 
vancomycin optimized by quantum-mechanical semiempirical calculations. Modified from [55].  
 
In addition, the interaction of the C8 chains functionalizing the silica matrix can 
also be simulated as well as to calculate its electrostatic potential (Fig. 10). As it can be 
observed in the figure, the charge density of pure silica is modified when introducing - 
CH2- groups with positive partial charge density, in such a way that the silica matrix, 
now displays a electrostatic potential gradient ranging from +1.34 to +0.005, unlike the 
native silica which exhibited only negative electron density. 
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Fig. (10). Optimized molecular model of a MCM-412.01 pore functionalized with random 
distributed C8 chains. Modified from [55].  
 
These simulations allowed us explaining an experimental fact already 
mentioned: the kinetic of delivery of the vancomycin in SBA-15 is fairly retarded when 
SBA15 is functionalized with C8 chains. As it was told, the kinetic constants were 
0.890 min-1/2 in SBA-15 and 0.068 min-1/2 in SBA-15-C8, that is to say, decrease in an 
order of magnitude with the functionalization. The theoretical molecular model 
calculations demonstrated that the electrostatic interactions were more intense in the 
SBA-15-C8 that in native SBA-15. This study demonstrated that modifying the matrix 
characteristics it can be controlled the delivery kinetic of vancomycin, which would 
suppose in this case, a clear advantage for its pharmacological applications in implants 
exposed to infections. 
However, when docking technique was applied, the theoretical model also 
demonstrated that although vancomycin could enters by size into the MCM-412.01 and 
also in the bigger size channels of SBA-15, the molecule is rejected by the matrix and 
only the small head of positive charge of vancomycin molecule can interact with the 
matrix (Fig. 11). Thus, the guest-host interaction is essentially of adsorption in the pores 
surface, where the hydrophobic C8 chains positively charged are able to exert a greater 
retention of the vancomycin molecules which contain a great proportion of negative 
charge (Fig. 8) with respect to non functionalized silica. 
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Fig. (11). Simulation by docking in aqueous medium of the entry of a vancomycin molecule into a 
MCM-41 channel. Modified from [55].  
 
Furthermore it is possible to know by molecular modeling if take place hydrogen 
bond interactions between the functionalized chains (for example with - NH2 groups) 
and the silica matrix. This would be an additional feature to modify the drug release 
because the channels structures could be altered with functionalizing. In a recent study 
using SBA-15 functionalized with 3-aminopropyl-triethoxy-silane (APTES) as host and 
Chicago Sky Blue 6B (CSB) as guest molecule, Doadrio et al [133] detected an unusual 
decrease of two orders of magnitude of the release constant of CSB from SBA-15-
APTES (34.7 min-1/2) with respect to SBA-15 (7.7 h1/2) [161]. This effect could be 
explained with the construction of an optimized molecular model of SBA-15 with the 
pore diameter of 5.45 nm (SBA-155.45). The mentioned decrease was explained 
watching that the functionalization with APTES forces the channel torsion by the 
formation of hydrogen bonds between Si-OH groups of SBA-155.45 and -NH2 groups of 
APTES (Fig. 12). 
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Fig. (12). Molecular modelling of a CSB-SBA-15-APTES system. A) Non optimized model. B) 
Optimized model. It is observed as the pore of the matrix is deformed and folded. In transparency 
the original pore model of SBA-15 without optimizing shown in A. Modified from [133].  
The folding of the pore caused by the –NH2 group decreasing the pore diameter 
more than that that takes place after an organic functionalization. Thus, a diameter 8.6 
nm was obtained for SBA-15-APTES when in the original native SBA-15 was 10.1 nm. 
For this reason a huge increase of the tortuosity channel takes place, slowing down the 
CSB release. This study also demonstrated the importance and relation that exists 
between both factors: pore size and tortuosity. 
In addition, in this case it is possible to establish by molecular modeling and 
docking, that the CSB molecule penetrates within the matrix channels establishing 
hydrogen bonds with silanol groups in both functionalized and not functionalized 
materials (Fig. 13). Moreover, as it is known, electrostatic interactions will be formed in 
both the outer part of the wall of the channels and inside the pores. 
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Fig. (13). Molecular model of CSB-SBA-15 system (in vacuum) showing the hydrogen bonds 
established between the silanol groups of the matrix, functionalised and not functionalised, and the 
CSB molecule. Modified from [133]. 
Previous results show that molecular modeling is a powerful tool for the rational 
explanation of how it works the adsorption and release mechanisms of a drug from a 
SMM. In addition, these calculations are potent tools to predict if a specific drug can or 
cannot be retained within the SMM channels. This fact is what actually will determine if 
the delivery is going to be controlled or not.  
CONCLUSIONS AND FUTURE PERSPECTIVES  
  As we have review in this article, the great advantage of the SMMs in drug 
administration comes from its pores structure forming cavities where the drug 
molecules can be hosted. With the functionalization of the mesoporous matrix, 
controlled release of the drug can be reached. However, we can go a step ahead if we 
took advantage of the possibilities to close the pore and to open it when is need to 
release the drug. That is to say, that the mesoporous material serves like an on off 
device. In addition, if we release the confined drug in the place where it is going to 
product its pharmacological action, in a denominated stimulus-response process, we 
would have a complete system of controlled and effective release of the drug. In this 
way, we can be able to reduce the dose of drug to high security levels, since we will 
release only the necessary amount of drug. 
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 As an example of stimuli-response system, our group used a driving mechanism 
based on the heat generated by an alternating magnetic field (AMF) in a system that 
encapsulates the drug on the base of complementary DNA strands [162]. Another 
example, now using a chemical stimulus, was the MCM-41-vancomycin-ATP system 
[163]. There the MCM-41 pores were blocked with nanoparticles able to form disulphur 
bonds. After the disulphur bridges reduction, the vancomycin and ATP molecules in the 
matrix were released.  
 Other authors investigated other stimuli including thermosensible polymers to 
control the release of the drug from the matrix [164, 165]; pH changes [166-168], 
optical luminescence [56], magnetic stimuli [169] or ultrasounds [170]. A paper of 
Mura et al in [171] and two of our group [172, 173] review the state of the art of these 
stimuli-response systems for the drug administration from nanocarriers. 
 Whereas the stimuli-response systems of controlled release continue its advance, 
the therapy with SMM-drug systems reviewed in the present article will come more 
effective and safe. As is well known in the progress of a new drug this two objectives 
mentioned are key factors, in I, II and III phases of development as well as in phase IV, 
once be commercialized. To this advance molecular modeling and docking techniques 
will play an important role, trough the development of more powerful computers and 
software.  
 But perhaps, the field with more promising future is the one of the galenic 
formulation of the drug, that is to say, its correct presentation for the administration in 
an effective, safe and convenient way for the patient. In this sense, the elaboration of 
SMMs nanoparticles has the advantages that we have already seen in the administration 
of the drug, with respect to conventional ones, in concrete the possibility of transporting 
the drug to a determined place of release. In addition nanoparticles present an important 
advantage with respect the traditional ones as powders or tablets: the nanoparticles can 
be administered easily by oral route and by a parenteral route which is not possible for 
the traditional. Nevertheless, it is important to take into consideration the problems that 
can arise from the use of nanoparticles in the human body, ones originated by the 
reproducibility of the particles and others by their interaction with the biological fluids 
and organs, like are biocompatibility, immune response and others that can affect to 
their security and effectiveness.  
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 In spite of these concerns, Nanotechnology is already beginning to change the 
way to design the systems for the administration and transport of drugs. As much be 
applied, and in the SMMs-drug are being already made, it will be able to advance 
enormously in the development of new therapies to cure diseases like cancer. In these 
therapies unloading the drug in the place of the tumor is crucial since not only increases 
the effectiveness, but that also makes the security. That way, it is possible to administer 
minor doses of a drug that is cytotoxic and besides the drug is coated inside the SMM 
matrix during the transport until the tumor avoiding that exerts its toxic effect in healthy 
cells.  
Great advances are also reached in related fields with future in the therapy of 
cancer. For example, the study of cellular lines with the anti-carcinogenic agent 
bleomycin conjugated with disaccharide, has demonstrated that bleomycin can be 
targeted to cultivated cancer cells [174, 175]. Moreover, relevant investigations in 
Nanomedicine were carried out with materials like liposomes or gold nanoparticles 
[176-178]. Of special relevance in this area, are the studies with Si-RNA that is a 
powerful approach silencing genes associated with a variety of pathologic conditions 
[179].  
Polymer or peptide based systems (organic), for instance, 3D fibrillar peptide 
hydrogels can achieve sustained antibody release [180-181]. The main drawback of 
these models is its foreseeable immunogenic character, a feature not exhibited by the 
SMMs. 
 A still unexplored field is the one of polypill based on SMMs. Polypill is a 
formulation composed of several drugs that are used for the arterial hypertension 
treatment. That way the patients, in a single daily administration, take his complete 
medication, instead of the habitual 4-5 daily takings of individual drugs. The SMM of 
big pore size as SBA-15 would allow to adsorb great amount of molecules of several 
antihypertensive drugs simultaneously and to release them of a controlled form 
throughout the day. This would suppose a great advantage for the patients, since it 
would be more difficult that they forgot to take his medication when ingesting a single 
daily dose. 
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GRAPHICAL ABSTRACT 
This article comprehensively reviews the host-guest systems for release drugs from 
ordered mesoporous silicas together possible future strategies to control demand the 
kinetics of delivery of drugs from these matrixes. 
 
 
 
The image of the graphical abstract in Grey Scale 
 56 
 
